Business
NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director
Extensive experience in Law, Finance, and Management of Public and Private Biotechnology CompaniesProven track record of creating value for
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Extensive experience in Law, Finance, and Management of Public and Private Biotechnology CompaniesProven track record of creating value for shareholdersNational Science Board Presidential Appointee, 2018-2024Former roles at Federal Deposit Insurance Corporation (FDIC) and E*Trade FinancialRADNOR, Pa., July 13, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): (\"NRx Pharmaceuticals\", or the \"Company\"), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer (\"CEO\") and a member of the Company's Board of Directors. The Company's interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer. \n\n \n \n \n \n \n \n\n \n@NRXP Board Appoints BioPharma Veteran and National Science Board Presidential Appointee to Lead NRx Pharmaceuticals, Inc. \"We are delighted to have attracted a candidate like Steve whose background and experience align with NRx Pharmaceuticals' current needs. Steve's passion to provide breakthrough therapies to address critical unmet needs positions the Company for success,\" said Patrick Flynn, a member of the Company's Board of Directors. \"We look forward to Steve's leadership of the Company in the next stages of growth to benefit patients, our shareholders, and the broader NRx team.\"\nMr. Willard brings a wealth of experience in the management of publicly traded biotechnology companies, together with his background in law and finance. Most recently, Mr. Willard served as CEO of Cellphire Therapeutics, where he grew the company and shepherded their revolutionary human platelet platform through key clinical trials, growing the company and significantly increasing the share price. Prior to Cellphire, he served as CEO of publicly traded Flamel Technologies now known as Avadel Pharmaceuticals. Mr. Willard is currently serving a six-year term from 2018-2024 as a presidential appointee to the National Science Board. \nMr. Willard's career in financial services includes government service as Associate Director of the Federal Deposit Insurance Corporation (FDIC), where he served in the United States Senior Executive Service (SES) from 1991-1994, and on the board of E*Trade Financial Services from 2000-2014. He has practiced law in New York, London, and W...